Estrogen exposure is one of the strongest risk factors for breast cancer 
development. Chemoprevention with selective estrogen receptor modulators (SERM), 
such as tamoxifen and raloxifene, has been shown in randomized controlled trials 
to reduce breast cancer incidence by up to 50% among high-risk women. Despite 
the strength of this evidence, there is significant underutilization of 
chemoprevention. Given the relatively few modifiable breast cancer risk factors, 
SERM use provides an important strategy for the primary prevention of this 
disease. Understanding factors which influence chemoprevention decision-making 
will inform efforts to implement breast cancer risk assessment and increase 
chemoprevention uptake in clinical practice. Cancer Prev Res; 10(11); 609-11. 
©2017 AACRSee related article by Holmberg et al., p. 625.